Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545232 · ClinicalTrials.gov registry record · Phase 3
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
NCT01545232 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 680 participants.
The verdict
NCT01545232, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
Study Summary
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion (\[MT\] (defined as receiving 10 units or more red blood cells (RBCs) within the first 24 hours). The goal of PROPPR is to improve the basis on which clinicians make decisions about transfusion protocols for massively bleeding patients. PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at Level I Adult Trauma Centers in North America.
Interventions
- BIOLOGICAL 1:1:1 Blood Transfusion Ratio
- BIOLOGICAL 1:1:2 Blood Transfusion Ratio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545232
The ClinicalTrials.gov registry entry for NCT01545232 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 1:1:1 Blood Transfusion Ratio is the first listed.
NCT01545232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545232 about?
NCT01545232 is a clinical study titled "Pragmatic, Randomized Optimal Platelet and Plasma Ratios". Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion (\[MT\] (defined as receiving 10 units or more red blood cells (RBCs) within the first 24...
What is the current status of trial NCT01545232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2012-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01545232?
The interventions under investigation include: 1:1:1 Blood Transfusion Ratio (BIOLOGICAL), 1:1:2 Blood Transfusion Ratio (BIOLOGICAL).
Who is sponsoring clinical trial NCT01545232?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.